Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic.


Autoria(s): Laskowitz, DT; Song, P; Wang, H; Mace, B; Sullivan, PM; Vitek, MP; Dawson, HN
Data(s)

01/11/2010

Formato

1983 - 1995

Identificador

http://www.ncbi.nlm.nih.gov/pubmed/20812776

J Neurotrauma, 2010, 27 (11), pp. 1983 - 1995

http://hdl.handle.net/10161/3293

1557-9042

Idioma(s)

ENG

en_US

Relação

J Neurotrauma

10.1089/neu.2010.1396

Journal of neurotrauma

Palavras-Chave #Amyloid beta-Peptides #Animals #Apolipoproteins E #Blotting, Western #Brain #Brain Injuries #Cytokines #Enzyme-Linked Immunosorbent Assay #Genetic Therapy #Gliosis #Humans #Immunohistochemistry #Male #Mice #Mice, Transgenic #Motor Activity #Neurodegenerative Diseases #Platelet-Derived Growth Factor #Polymorphism, Genetic #Psychomotor Performance #RNA, Messenger #Tumor Necrosis Factor-alpha #tau Proteins
Tipo

Journal Article

Cobertura

United States

Resumo

Cognitive impairment is common following traumatic brain injury (TBI), and neuroinflammatory mechanisms may predispose to the development of neurodegenerative disease. Apolipoprotein E (apoE) polymorphisms modify neuroinflammatory responses, and influence both outcome from acute brain injury and the risk of developing neurodegenerative disease. We demonstrate that TBI accelerates neurodegenerative pathology in double-transgenic animals expressing the common human apoE alleles and mutated amyloid precursor protein, and that pathology is exacerbated in the presence of the apoE4 allele. The administration of an apoE-mimetic peptide markedly reduced the development of neurodegenerative pathology in mice homozygous for apoE3 as well as apoE3/E4 heterozygotes. These results demonstrate that TBI accelerates the cardinal neuropathological features of neurodegenerative disease, and establishes the potential for apoE mimetic therapies in reducing pathology associated with neurodegeneration.